Independent Nycomed US names ex-King Pharma execs as CEO, COO and CFO

1 August 2011

Nycomed US Inc has announced the appointment of Brian Markison as president and chief executive Officer and member of the Board for what will be the newly-created standalone corporation created following the closing of the 9.6 billion-euro acquisition of independent Swiss drugmaker Nycomed A/S by Japan’s Takeda Pharmaceuticals (The Pharma Letter May 19).

The company also appointed Jeff Bailey to the newly-created position of chief operating officer, and John Golubieski as the chief financial officer. Hakan Bjorklund, CEO of Nycomed A/S is chairman of the board of Nycomed US.

Mr Markison formerly served as chairman and CEO of King Pharmaceuticals, which was acquired by Pfizer (TPL October 13, 2010), which he joined as COO before being promoted to president and CEO in 2004 and elected to Chairman in 2007. Mr Bailey formerly served as the chief commercial officer of King-Pfizer Pharmaceuticals, while Mr Golubieski spent the last six years as the senior vice president of financial planning and analysis at King.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK